AI assistant
Sending…
Protara Therapeutics, Inc. — Director's Dealing 2019
Jan 23, 2019
34057_dirs_2019-01-23_9fe5c0b5-55e1-48ad-9da6-069e38404790.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PROTEON THERAPEUTICS INC (PRTO)
CIK: 0001359931
Period of Report: 2019-01-18
Reporting Person: Hartman Bradley J (VP, People)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-01-18 | Stock Option (Right to Buy) | $2.64 | A | 70000 | Acquired | 2029-01-17 | Common Stock, $0.001 par value (70000) | Direct |
Footnotes
F1: The options were granted on January 18, 2019 and the shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments.
More from Protara Therapeutics, Inc.
Capital/Financing Update
2026
May 28
Capital/Financing Update
2026
May 13
Interim / Quarterly Report
2026
May 13
Report Publication Announcement
2026
May 13
Regulatory Filings
2026
Mar 30
Regulatory Filings
2026
Feb 24
Capital/Financing Update
2026
Feb 2
Director's Dealing
2026
Jan 27
Director's Dealing
2026
Jan 27
Director's Dealing
2026
Jan 27